The UK Competition and Markets Authority issued a statement on May 20 inviting relevant parties to comment on the impact of Roche's acquisition of the LumiraDx technology platform on competition before June 3. The regulator has yet to launch an official investigation into the deal.
英国竞争与市场管理局开始调查罗氏收购LumiraDx平台案
The UK Competition and Markets Authority begins investigation into Roche's acquisition of the LumiraDx platform
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.